Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
I thank Valiyil and Schechter for their letter1 to the editorial related to clinical studies of lesinurad.2 The letter correctly states that the 200 mg lesinurad dose is the only (initial and maximum) dose that should be prescribed to patients, always in combination with a xanthine oxidase inhibitor. The letter provides an important clarification regarding the dose of lesinurad that was approved by the regulatory agencies. Based on higher toxicity, the sponsor did not pursue regulatory approval (Food and Drug Administration (FDA) and European Medicines Agency (EMEA)) for …
Handling editor Tore K Kvien
Competing interests JAS has received research grants from Takeda and Savient and consultant fees from Savient, Takeda, Regeneron, Merz, Iroko, Bioiberica, Crealta/Horizon and Allergan pharmaceuticals, WebMD, UBM LLC and the American College of Rheumatology. JAS serves as the principal investigator for an investigator-initiated study funded by Horizon pharmaceuticals through a grant to DINORA, Inc, a 501 (c)(3) entity. JAS is a member of the executive of OMERACT, an organisation that develops outcome measures in rheumatology and receives arms-length funding from 36 companies; a member of the American College of Rheumatology’s (ACR) Annual Meeting Planning Committee (AMPC); Chair of the ACR Meet-the-Professor, Workshop and Study Group Subcommittee; and a member of the Veterans Affairs Rheumatology Field Advisory Committee. JAS is the editor and the Director of the UAB Cochrane Musculoskeletal Group Satellite Center on Network Meta-analysis.
Provenance and peer review Commissioned; internally peer reviewed.